NEUMUSK Group Research, Department of Physiotherapy, Facultad de Ciencias de La Salud, Universidad Católica de Ávila, Ávila, Spain.
Faculty of Nursing, Physiotherapy and Podiatry Universidad Complutense of Madrid, Madrid, Spain.
Chron Respir Dis. 2024 Jan-Dec;21:14799731241255967. doi: 10.1177/14799731241255967.
COVID-19 demonstrated the possibility of neurological complications such as loss of sense of smell and taste, together with respiratory problems. Respiratory training and rehabilitation of neurological sequelae are essential to improve respiratory function and thus quality of life, and the aim of this study is to evaluate the efficacy of a pulmonary and neurological rehabilitation program.
To apply a treatment to reduce dyspnea, increase exertional capacity, increase vital capacity and respiratory muscle strength, together with an increase in olfactory and gustatory sensitivity in post-SARS-CoV-2 patients.
A randomised controlled experimental study was conducted in 220 patients with a medical diagnosis of COVID-19 and more than 5 months of evolution, dyspnoea or perceived fatigue, including olfactory and gustatory perception problems, of whom 200 patients completed the study. 100 patients were randomly assigned to the intervention group, consisting of an inspiratory training treatment plan (Powerbreathe Plus®) combined with aerobic exercise and olfactory gustatory treatment for 31 days, and 100 patients to the control group, for 31 days without any type of therapy.
The study was conducted in post-Covid-19 patients for 5 months. Two hundred patients were divided into an intervention group ( = 100) and a control group ( = 100). The comparison between the groups showed significant differences in spirometric variables; forced vital capacity ( < .001; Eta2 (0.439); Mean: 0,6135), the ratio between both FEV1/FVC ( < 0.01; Eta2 (0.728); Mean:9,313), peak inspiratory pressure ( < 0.01; Eta2 (0.906); Mean:4,526); changes were observed in dyspnoea measured with the modified Borg scale ( < 0.01; Eta2 (0.811); Mean:1,481) and the modified Medical Research Council scale ( < 0.01; Eta2 (0.881); Mean: 0.777); finally, changes were found in neurological variables, in the questions of the Singapore Smell and Taste Questionnaire, How was your sense of smell after treatment? ( < 0.01; Eta2 (0.813); Mean: 1,721) and How is your sense of taste after treatment? ( < 0.01; Eta2 (0.898); Mean: 1,088).
The implementation of a respiratory rehabilitation treatment plan with the Powerbreathe Plus® device, aerobic exercise and neurorehabilitation with olfactory and gustatory training, is a therapeutic option against respiratory and neurological sequelae in patients who have suffered such sequelae due to the SARS-CoV-2 virus. Clinicaltrials.gov: NCT05195099. First posted 18/01/2022; Last Update Posted 29/06/2022.
COVID-19 表现出了发生嗅觉和味觉丧失等神经并发症的可能性,同时还伴有呼吸道问题。呼吸训练和神经后遗症康复对于改善呼吸功能和生活质量至关重要,本研究的目的是评估肺部和神经康复计划的疗效。
应用一种治疗方法来减轻呼吸困难,增加运动能力,增加肺活量和呼吸肌力量,并提高 SARS-CoV-2 后患者的嗅觉和味觉敏感性。
对 220 名经医学诊断患有 COVID-19 且病程超过 5 个月、存在呼吸困难或自觉疲劳(包括嗅觉和味觉感知问题)的患者进行了一项随机对照实验研究,其中 200 名患者完成了研究。100 名患者被随机分配到干预组,包括使用 Powerbreathe Plus®进行吸气训练治疗方案,以及 31 天的有氧运动和嗅觉味觉治疗;100 名患者被分配到对照组,31 天内不接受任何类型的治疗。
该研究对 COVID-19 后患者进行了 5 个月的随访。200 名患者被分为干预组(n=100)和对照组(n=100)。组间比较显示,在肺量计变量方面存在显著差异;用力肺活量(<0.001;Eta2(0.439);平均值:0.6135)、FEV1/FVC 比值(<0.01;Eta2(0.728);平均值:9.313)、吸气峰压(<0.01;Eta2(0.906);平均值:4.526);使用改良 Borg 量表测量的呼吸困难(<0.01;Eta2(0.811);平均值:1.481)和改良医学研究委员会量表(<0.01;Eta2(0.881);平均值:0.777)均有改善;最后,在神经变量方面也有变化,新加坡嗅觉味觉问卷的问题中,治疗后您的嗅觉如何?(<0.01;Eta2(0.813);平均值:1.721)和治疗后您的味觉如何?(<0.01;Eta2(0.898);平均值:1.088)。
使用 Powerbreathe Plus®设备进行呼吸康复治疗、有氧运动和嗅觉味觉神经康复,是针对因 SARS-CoV-2 病毒而出现此类后遗症的患者的呼吸和神经后遗症的治疗选择。Clinicaltrials.gov:NCT05195099。首次发布于 2022 年 1 月 18 日;最后更新于 2022 年 6 月 29 日。